Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis

New England Journal of Medicine

Volumn 377, Issue 21, 2017, Pages 2063-2072

  Diehl, Anna M ^a   Day, Christopher ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMINOTRANSFERASE; BIOLOGICAL MARKER; CHEMOKINE RECEPTOR CCR2 ANTAGONIST; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 21; GALECTIN 3; LIVER PROTECTIVE AGENT; LYSYL OXIDASE LIKE 2 INHIBITOR; OBETICHOLIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PIOGLITAZONE; STRESS ACTIVATED KINASE 1 INHIBITOR; UNCLASSIFIED DRUG;

AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL FEATURE; COLOSTRUM; DIAGNOSTIC IMAGING; ENVIRONMENTAL FACTOR; EPIDEMIOLOGICAL DATA; EPIGENETICS; FATTY LIVER; GENETIC SCREENING; HEREDITY; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIVER FIBROSIS; LIVER FUNCTION TEST; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOGENESIS; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; WEIGHT GAIN; ADULT; CHILD; COMPLICATION; DISEASE EXACERBATION; LIVER; LIVER CIRRHOSIS; PATHOLOGY;

ADULT; CHILD; DISEASE PROGRESSION; HUMANS; LIVER; LIVER CIRRHOSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY;

EID: 85034771842     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1503519     Document Type: Article

References (59)

1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease — meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73-84.
2. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011;140:124-31.
3. Adams LA, Harmsen S, St Sauver JL, et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol 2010;105:1567-73.
4. Younossi ZM, Stepanova M, Rafiq N, et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 2011;53:1874-82.
5. Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015;61:1547-54.
6. Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015;149(2):389-97.e10.
7. Angulo P, Machado MV, Diehl AM. Fibrosis in nonalcoholic fatty liver disease: mechanisms and clinical implications. Semin Liver Dis 2015;35:132-45.
8. Hardy T, Oakley F, Anstee QM, Day CP. Nonalcoholic fatty liver disease: pathogenesis and disease spectrum. Annu Rev Pathol 2016;11:451-96.
9. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011;141:1249-53.
10. Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 2015;148:547-55.
11. Welzel TM, Graubard BI, Quraishi S, et al. Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol 2013;108:1314-21.
12. Wong CR, Nguyen MH, Lim JK. Hepato-cellular carcinoma in patients with nonalcoholic fatty liver disease. World J Gastroenterol 2016;22:8294-303.
13. Marengo A, Rosso C, Bugianesi E. Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annu Rev Med 2016;67:103-17.
14. Berentzen TL, Gamborg M, Holst C, Sørensen TI, Baker JL. Body mass index in childhood and adult risk of primary liver cancer. J Hepatol 2014;60:325-30.
15. Younossi ZM, Blissett D, Blissett R, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 2016;64:1577-86.
16. Yamaguchi K, Yang L, McCall S, et al. Diacylglycerol acyltranferase 1 anti-sense oligonucleotides reduce hepatic fibrosis in mice with nonalcoholic steatohepatitis. Hepatology 2008;47:625-35.
17. Heymann F, Tacke F. Immunology in the liver — from homeostasis to disease. Nat Rev Gastroenterol Hepatol 2016;13: 88-110.
18. Arrese M, Cabrera D, Kalergis AM, Feldstein AE. Innate immunity and inflammation in NAFLD/NASH. Dig Dis Sci 2016;61:1294-303.
19. Ji C, Kaplowitz N, Lau MY, Kao E, Petrovic LM, Lee AS. Liver-specific loss of glucose-regulated protein 78 perturbs the unfolded protein response and exacerbates a spectrum of liver diseases in mice. Hepatology 2011;54:229-39.
20. Diehl AM. Lessons from animal models of NASH. Hepatol Res 2005;33:138-44.
21. Rangwala F, Guy CD, Lu J, et al. Increased production of sonic hedgehog by ballooned hepatocytes. J Pathol 2011;224: 401-10.
22. Guy CD, Suzuki A, Abdelmalek MF, Burchette JL, Diehl AM. Treatment response in the PIVENS trial is associated with decreased Hedgehog pathway activity. Hepatology 2015;61:98-107.
23. Severson TJ, Besur S, Bonkovsky HL. Genetic factors that affect nonalcoholic fatty liver disease: a systematic clinical review. World J Gastroenterol 2016;22: 6742-56.
24. Anstee QM, Seth D, Day CP. Genetic factors that affect risk of alcoholic and nonalcoholic fatty liver disease. Gastroenterology 2016;150(8):1728-44.e7.
25. Dongiovanni P, Valenti L. Genetics of nonalcoholic fatty liver disease. Metabolism 2016;65:1026-37.
26. Kahali B, Halligan B, Speliotes EK. Insights from genome-wide association analyses of nonalcoholic fatty liver disease. Semin Liver Dis 2015;35:375-91.
27. Loomba R, Schork N, Chen CH, et al. Heritability of hepatic fibrosis and steatosis based on a prospective twin study. Gastroenterology 2015;149:1784-93.
28. Bian EB, Zhao B, Huang C, et al. New advances of DNA methylation in liver fibrosis, with special emphasis on the crosstalk between microRNAs and DNA methylation machinery. Cell Signal 2013; 25:1837-44.
29. Gabory A, Attig L, Junien C. Developmental programming and epigenetics. Am J Clin Nutr 2011;94:Suppl:1943S-1952S.
30. Godfrey KM, Costello PM, Lillycrop KA. Development, epigenetics and metabolic programming. Nestle Nutr Inst Workshop Ser 2016;85:71-80.
31. Lee JH, Friso S, Choi SW. Epigenetic mechanisms underlying the link between non-alcoholic fatty liver diseases and nutrition. Nutrients 2014;6:3303-25.
32. Lee YS. Genetics of nonsyndromic obesity. Curr Opin Pediatr 2013;25:666-73.
33. Page A, Mann DA, Mann J. The mechanisms of HSC activation and epigenetic regulation of HSCs phenotypes. Curr Pathobiol Rep 2014;2:163-70.
34. Mann DA. Epigenetics in liver disease. Hepatology 2014;60:1418-25.
35. Hardy T, Zeybel M, Day CP, et al. Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in nonalcoholic fatty liver disease. Gut 2017;66: 1321-8.
36. Cope K, Risby T, Diehl AM. Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis. Gastroenterology 2000;119:1340-7.
37. Nair S, Cope K, Risby TH, Diehl AM. Obesity and female gender increase breath ethanol concentration: potential implications for the pathogenesis of nonalcoholic steatohepatitis. Am J Gastroenterol 2001;96:1200-4.
38. Li Z, Yang S, Lin H, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003;37: 343-50.
39. Machado MV, Cortez-Pinto H. Diet, microbiota, obesity, and NAFLD: a dangerous quartet. Int J Mol Sci 2016;17:481.
40. Federico A, Dallio M, Godos J, Loguercio C, Salomone F. Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence. Transl Res 2016;167:116-24.
41. Kirpich IA, Marsano LS, McClain CJ. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease. Clin Biochem 2015;48: 923-30.
42. Vanni E, Bugianesi E. The gut-liver axis in nonalcoholic fatty liver disease: another pathway to insulin resistance? Hepatology 2009;49:1790-2.
43. Boursier J, Mueller O, Barret M, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 2016;63:764-75.
44. Dibner C, Gachon F. Circadian dysfunction and obesity: is leptin the missing link? Cell Metab 2015;22:359-60.
45. Fleet T, Stashi E, Zhu B, et al. Genetic and environmental models of circadian disruption link SRC-2 function to hepatic pathology. J Biol Rhythms 2016;31:443-60.
46. Kettner NM, Voicu H, Finegold MJ, et al. Circadian homeostasis of liver metabolism suppresses hepatocarcinogenesis. Cancer Cell 2016;30:909-24.
47. Yamamoto Y, Moore R, Goldsworthy TL, Negishi M, Maronpot RR. The orphan nuclear receptor constitutive active/androstane receptor is essential for liver tumor promotion by phenobarbital in mice. Cancer Res 2004;64:7197-200.
48. Wahlang B, Beier JI, Clair HB, et al. Toxicant-associated steatohepatitis. Toxi-col Pathol 2013;41:343-60.
49. Yokohama S, Yoneda M, Haneda M, et al. Therapeutic efficacy of an angioten-sin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004;40:1222-5.
50. VanWagner LB, Rinella ME. Extra-hepatic manifestations of nonalcoholic fatty liver disease. Curr Hepatol Rep 2016; 15:75-85.
51. Satapathy SK, Sanyal AJ. Epidemiology and natural history of nonalcoholic fatty liver disease. Semin Liver Dis 2015; 35:221-35.
52. Lonardo A, Sookoian S, Chonchol M, Loria P, Targher G. Cardiovascular and systemic risk in nonalcoholic fatty liver disease — atherosclerosis as a major player in the natural course of NAFLD. Curr Pharm Des 2013;19:5177-92.
53. Hossain N, Afendy A, Stepanova M, et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7:1224-9.
54. Golabi P, Sayiner M, Fazel Y, Koenig A, Henry L, Younossi ZM. Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis. Expert Rev Gastroenterol Hepatol 2016;10: 63-71.
55. Sanyal AJ, Friedman SL, McCullough AJ, Dimick-Santos L. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration joint workshop. Hepatology 2015;61:1392-405.
56. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362:1675-85.
57. Noureddin M, Zhang A, Loomba R. Promising therapies for treatment of nonalcoholic steatohepatitis. Expert Opin Emerg Drugs 2016;21:343-57.
58. Brodosi L, Marchignoli F, Petroni ML, Marchesini G. NASH: a glance at the landscape of pharmacological treatment. Ann Hepatol 2016;15:673-81.
59. Lassailly G, Caiazzo R, Pattou F, Mathurin P. Perspectives on treatment for nonalcoholic steatohepatitis. Gastroenterology 2016;150:1835-48.